登录新浪财经APP 搜索【信披】查看更多考评等级 【导读】金迪克总经理张建辉因病逝世，享年67岁 中国基金报记者 晨曦 9月10日晚间，金迪克发布公告称，收到公司总经理张建辉家属通知，张建辉因病于近日不幸逝世，享年67岁。 金迪克称，张建辉自2015年起一直为公司或公司前身江苏金迪克生物技术有限公司的主要股东之一，并于2023年10月被聘任为公司总经理。张建辉长期伴 随并支持公司发展壮大，在担任公司总经理期间，勤勉尽责、恪尽职守，认真履行了作为公司高级管理人员应尽的责任和义务，为公司经营发展做出了重 要贡献。 金迪克董事会、监事会、高级管理人员及全体员工对张建辉为公司所做的努力和贡献深表感谢，对张建辉的逝世致以沉痛哀悼，并向其家属致以深切慰 问。 截至该公告披露日，张建辉持有金迪克股份568万余股，占总股本的4.61%。2025年中报显示，张建辉为金迪克第三大股东。 | 序号 | 股东名称 | | 持股数量(股) | 占总股本比例(%) | | --- | --- | --- | --- | --- | | 1 | 张良斌 (1) (2) 实控人 | 董监高 | 37,869,008 | 30.74 | | ...

据证券之星公开数据整理，近期金迪克（688670）发布2025年中报。截至本报告期末，公司营业总收入 352.42万元，同比上升7.18%，归母净利润-3965.31万元，同比上升2.97%。按单季度数据看，第二季度 营业总收入6.04万元，同比上升103.49%，第二季度归母净利润-2207.18万元，同比下降13.91%。本报告 期金迪克存货明显上升，存货同比增幅达83.9%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率94.77%，同比增21.99%，净利率-1125.15%，同 比增9.47%，销售费用、管理费用、财务费用总计3454.96万元，三费占营收比980.34%，同比减 30.86%，每股净资产10.05元，同比减6.94%，每股经营性现金流-0.69元，同比增4.24%，每股收益-0.32 元，同比增3.03% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 328.82万 | 352.42万 | 7.18% | | 归母浄利润（元） | -4086.71万 | -3965.31万 | ...

Core Viewpoint - The price war in the influenza vaccine market has significantly impacted the financial performance of Jindike, leading to a substantial decline in revenue and profitability for the second consecutive year [1][5]. Financial Performance - In 2024, Jindike reported operating revenue of 80.8027 million yuan, a year-on-year decrease of 39.96%, resulting in a net loss of 93.5028 million yuan [2][6]. - The company has experienced a continuous decline in performance, with losses reported for three consecutive years from 2021 to 2023 [6]. - The price reduction of the four-valent influenza vaccine has contributed to the company's financial struggles, with the average price dropping from 128 yuan to 88 yuan, a decrease of 31.25% [6][7]. Product and Sales Performance - Jindike's only marketed product is the four-valent influenza virus split vaccine, which saw a 30% price reduction in 2024, leading to a significant compression of profit margins [3][8]. - The sales volume of the four-valent influenza vaccine was 1.1697 million doses in 2024, a year-on-year decrease of 15.32% [9]. - The company's gross margin for the four-valent influenza vaccine was 62.61% in 2024, down 15.2 percentage points from the previous year [8]. R&D and Future Plans - To reduce reliance on a single product, Jindike has increased its R&D investment, which accounted for 51.81% of its revenue in 2024, totaling approximately 41.8629 million yuan [12][13]. - The company is focusing on the development of a rabies vaccine, which has completed Phase III clinical trials and is currently undergoing product registration [4][15]. - Jindike is also expanding its product pipeline to include vaccines for chickenpox, shingles, and pneumococcal diseases, with ongoing clinical trials for its pediatric four-valent influenza vaccine [16].